



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Ref: ADL/SE/2025-26/76
March 7, 2026

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sub: Investment in Pinnacle Life Science Private Limited, Wholly Owned Subsidiary of the Company.

This is to inform you that the Finance & Investment Committee at its Meeting held on **Saturday, March 7, 2026**, approved the investment in equity shares of Pinnacle Life Science Private Limited, wholly owned subsidiary of the Company, upto an aggregate value of INR 10,00,00,000 (Indian Rupees Ten Crore only), by way of subscription to the Rights Issue.

The details as required under SEBI Listing Regulations read with SEBI Mater Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are as under:

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Pinnacle Life Science Private Limited (CIN: U24232HP2003PTC030912) Turnover as on March 31, 2025 is Rs. 25,392.38 Lakhs
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Pinnacle Life Science Private Limited (Pinnacle) is a Wholly Owned Material Subsidiary of the Company. The proposed subscription falls within the ambit of related party transactions. The Company is interested in proposed transaction only to the extent of its Shareholding in the Pinnacle. The transaction is being carried out at arm’s length basis.
3	Industry to which the entity being acquired belongs	Pharmaceuticals
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The investment proceeds will be used by Pinnacle for financing the cost towards expansion/capex plan and other general corporate purpose. Its business is in line with the business of Aarti Drugs Limited.



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable								
6	Indicative time period for completion of the acquisition	Share will be allotted on or before March 20, 2026 by Pinnacle								
7	Consideration- whether cash consideration or share swap or any other form and details of the same	Cash								
8	Cost of acquisition and/or the price at which the shares are acquired	Rs. 10,00,00,000 (Rupees Ten Crore only) 78125 Equity shares of face value of Rs. 10 each will be allotted by Pinnacle at a premium of Rs. 1270 per share.								
9	Percentage of shareholding / control acquired and / or number of shares acquired	Subscription to 78125 Equity Shares of Rs. 10 each. Post allotment shareholding shall remain same i.e. Pinnacle will continue to be a wholly owned subsidiary								
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information	<p>The Pinnacle is primarily involved in manufacturing of pharmaceutical formulations. With a diverse portfolio spanning oncology, cardiovascular, anti-infectives, and diabetics, Pinnacle exports its products to over 30 countries. Pinnacle also has domestic presence in Indian market.</p> <p>Date of Incorporation: January 15, 2003</p> <p>The turnover of Pinnacle for last 3 years is given below:</p> <table border="1"><thead><tr><th>Financial Year</th><th>Turnover (Rs. in Lakhs)</th></tr></thead><tbody><tr><td>2024-25</td><td>25,392.38</td></tr><tr><td>2023-24</td><td>31,465.76</td></tr><tr><td>2022-23</td><td>28,657.44</td></tr></tbody></table> <p>Country: Pinnacle is incorporated in India</p>	Financial Year	Turnover (Rs. in Lakhs)	2024-25	25,392.38	2023-24	31,465.76	2022-23	28,657.44
Financial Year	Turnover (Rs. in Lakhs)									
2024-25	25,392.38									
2023-24	31,465.76									
2022-23	28,657.44									

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE

COMPANY SECRETARY & COMPLIANCE OFFICER

ICSI M. No.: F12932